Market Overview

UPDATE: St. Jude Medical Resolves FDA Warning

Related STJ
St. Jude Medical Receives CE Mark for New Infinity Deep Brain Stimulation System and Directional DBS Lead
St. Jude Confirms 5-Year Data from FAME Trial Further Confirms Sustained, Long Term Benefit of FFR-Guided PCI
The Worst Of October's 742 All CCC Companies (Seeking Alpha)

St. Jude Medical, Inc. (NYSE: STJ), a global medical device company, today
announced that it has been notified by the U.S. Food and Drug
Administration (FDA) that issues cited in the Plano, Texas, facility's warning
letter have been addressed.

“We're pleased to have resolved the concerns identified by the FDA at our
Plano manufacturing facility," said Daniel J. Starks, chairman, president and
chief executive officer at St. Jude Medical. “We take quality and compliance
seriously and are committed to meeting and exceeding patient, physician and
regulator expectations in these areas.”

Posted-In: News FDA Press Releases


Related Articles (STJ)

Get Benzinga's Newsletters